Form 4: BioCryst Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

BioCryst Pharmaceuticals' Chief R&D Officer, Helen M. Thackray, sold 7,150 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Helen M. Thackray, Chief R&D Officer at BioCryst Pharmaceuticals, sold 7,150 shares of common stock on December 14, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of previously granted restricted stock units.
• The shares were sold at a price of $7.53 per share.
• Following the transaction, Ms. Thackray directly owns 264,989 shares of BioCryst Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine transaction for an executive to cover tax obligations. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales by executives.
• The number of shares sold and the price are specific to this transaction and do not provide a direct comparison to other companies without further context.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, insider trading, Form 4, stock sale, executive compensation, restricted stock units, tax obligations, Helen M. Thackray, Chief R&D Officer